Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Cardiovascular disorders (CVD) are the primary cause of death worldwide. Multiple factors have been accepted to cause cardiovascular diseases; among them, smoking, physical inactivity, unhealthy eating habits, age, and family history are flag-bearers. Individuals at risk of developing CVD are suggested to make drastic habitual changes as the primary intervention to prevent CVD; however, over time, the disease is bound to worsen. This is when secondary interventions come into play, including antihypertensive, anti-lipidemic, anti-anginal, and inotropic drugs. These drugs usually undergo surgical intervention in patients with a much higher risk of heart failure. These therapeutic agents increase the survival rate, decrease the severity of symptoms and the discomfort that comes with them, and increase the overall quality of life. However, most individuals succumb to this disease. None of these treatments address the molecular mechanism of the disease and hence are unable to halt the pathological worsening of the disease. Gene therapy offers a more efficient, potent, and important novel approach to counter the disease, as it has the potential to permanently eradicate the disease from the patients and even in the upcoming generations. However, this therapy is associated with significant risks and ethical considerations that pose noteworthy resistance. In this review, we discuss various methods of gene therapy for cardiovascular disorders and address the ethical conundrum surrounding it.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Current gene therapy - (2024) vom: 29. Jan. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wal, Pranay [VerfasserIn] |
---|
Links: |
---|
Themen: |
Cardiovascular diseases |
---|
Anmerkungen: |
Date Revised 30.01.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.2174/0115665232268840231222035423 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367791706 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM367791706 | ||
003 | DE-627 | ||
005 | 20240130232300.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240130s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/0115665232268840231222035423 |2 doi | |
028 | 5 | 2 | |a pubmed24n1275.xml |
035 | |a (DE-627)NLM367791706 | ||
035 | |a (NLM)38288826 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wal, Pranay |e verfasserin |4 aut | |
245 | 1 | 0 | |a Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 30.01.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a Cardiovascular disorders (CVD) are the primary cause of death worldwide. Multiple factors have been accepted to cause cardiovascular diseases; among them, smoking, physical inactivity, unhealthy eating habits, age, and family history are flag-bearers. Individuals at risk of developing CVD are suggested to make drastic habitual changes as the primary intervention to prevent CVD; however, over time, the disease is bound to worsen. This is when secondary interventions come into play, including antihypertensive, anti-lipidemic, anti-anginal, and inotropic drugs. These drugs usually undergo surgical intervention in patients with a much higher risk of heart failure. These therapeutic agents increase the survival rate, decrease the severity of symptoms and the discomfort that comes with them, and increase the overall quality of life. However, most individuals succumb to this disease. None of these treatments address the molecular mechanism of the disease and hence are unable to halt the pathological worsening of the disease. Gene therapy offers a more efficient, potent, and important novel approach to counter the disease, as it has the potential to permanently eradicate the disease from the patients and even in the upcoming generations. However, this therapy is associated with significant risks and ethical considerations that pose noteworthy resistance. In this review, we discuss various methods of gene therapy for cardiovascular disorders and address the ethical conundrum surrounding it | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Cardiovascular diseases | |
650 | 4 | |a Gene | |
650 | 4 | |a Gene Therapy | |
650 | 4 | |a Gene editing technology | |
650 | 4 | |a Non-viral vector. | |
650 | 4 | |a Vectors | |
700 | 1 | |a Aziz, Namra |e verfasserin |4 aut | |
700 | 1 | |a Pratap Singh, Chetan |e verfasserin |4 aut | |
700 | 1 | |a Rasheed, Azhar |e verfasserin |4 aut | |
700 | 1 | |a Tyagi, Lalit Kumar |e verfasserin |4 aut | |
700 | 1 | |a Agrawal, Ankur |e verfasserin |4 aut | |
700 | 1 | |a Wal, Ankita |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current gene therapy |d 2001 |g (2024) vom: 29. Jan. |w (DE-627)NLM119780747 |x 1875-5631 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:29 |g month:01 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/0115665232268840231222035423 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 29 |c 01 |